PIKfyve-IN-5
PIKfyve-IN-5 is a PIKfyve inhibitor (IC50 = 32 nM) with selective antiviral activity. PIKfyve-IN-5 inhibits PIKfyve and blocks the release of the viral genome from endosomes into the cytosol by sequestering viral particles within swollen spherical vacuoles. PIKfyve-IN-5 exhibits antiviral activity against SARS-CoV-2 in human lung epithelial cells. PIKfyve-IN-5 can be used for research on SARS-CoV-2 infection.
For research use only. We do not sell to patients.
- Formula: C20H14N4O2S
- Molecular Weight:374.42
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Calu-3 | EC50 |
2.61 μM
|
Antiviral activity against SARS-CoV-2 in human lung epithelial Calu-3 cells pretreated for 1 hour prior to infection at MOI 0.05, measured at 24 hours post-infection by nanoluciferase assay.
Antiviral activity against SARS-CoV-2 in human lung epithelial Calu-3 cells pretreated for 1 hour prior to infection at MOI 0.05, measured at 24 hours post-infection by nanoluciferase assay.
|
42570378 |
In Vitro
PIKfyve-IN-5 (compound 32) is a potent and selective PIKfyve inhibitor with an IC50 of 0.064 μM in the biochemical ADP-Glo assay, and shows no significant inhibition against a panel of 70 kinases at 10 μM[1].
PIKfyve-IN-5 (24 h) exhibits potent anti-SARS-CoV-2 activity in Calu-3 cells with an EC50 of 2.61 μM, and no cytotoxicity is detected at concentrations up to 20 μM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Chemical Information
-
Molecular Weight 374.42
-
Formula C20H14N4O2S
-
SMILES
COC(C=C(C=C1)C2=NC3=C(SN=C3N=C2)C#CC4=CC=CN=C4)=C1OC
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)